Clinical Trial

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 19, 2023 (before its estimated April 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-03-28; most recent amendment 2025-07-17.
Status change: Recruiting → Active, Not Recruiting 2023-05-18
Status change: Not Yet Recruiting → Recruiting 2018-07-02
Trial Details
NCT Number NCT03488667
Lead Sponsor University of Kansas Medical Center
Collaborators: Merck Sharp & Dohme LLC
Conditions Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
Enrollment 40 participants
Start Date 2018-06-27
Primary Completion 2024-04-30 (estimated)
Study Completion 2025-04-30 (estimated)
Updated on ClinicalTrials.gov 2023-05-19